WO2006097090A1 - Retinol for reducing risk factors of arteriosclerosis and/or increasing insulin sensitivity - Google Patents
Retinol for reducing risk factors of arteriosclerosis and/or increasing insulin sensitivity Download PDFInfo
- Publication number
- WO2006097090A1 WO2006097090A1 PCT/DE2006/000474 DE2006000474W WO2006097090A1 WO 2006097090 A1 WO2006097090 A1 WO 2006097090A1 DE 2006000474 W DE2006000474 W DE 2006000474W WO 2006097090 A1 WO2006097090 A1 WO 2006097090A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- retinol
- insulin sensitivity
- vitamin
- risk factors
- arteriosclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the invention has the production of a medicament for the
- Beta-carotene is a precursor that is widely distributed and is nutritionally converted to retinol by digestion. The immediate food intake of beta-carotene is therefore also an indirect supply of retinol.
- the term retinol is synonymous with the
- Vitamin A is the generic term, among other vitamin A1 but also other compounds, For example, vitamin A 2 understood. In the following, the scientific studies of the oral administration of vitamin A on atherosclerosis and / or insulin sensitivity are described.
- endothelial cells, platelets and monocytes respond to various stimuli, which might include, but are not limited to, oxidative stress, membrane-bound adhesion molecules, express these monocytes circulating these endothelial adhesion molecules and control their introduction into the subendothelium. In this way, atherogenic processes can be induced.
- Detached adhesion molecules also known as soluble, are therefore considered as serum markers for the risk of coronary heart disease. They have a similar function as the CRP, as an abbreviation for the C-reactive protein.
- the subjects were given a liquid test meal once without and once with retinol (9 mg) with an interval of 8 days and a nursery period of at least 12 hours.
- the test meal was composed of 58 g milkfat, 70 g sucrose, 5 g lactose, 30 g protein, 600 mg cholesterol, 10 g ethanol.
- Adhesion molecules slCAM-1 soluble intercellular adhesion molecule
- sVCAM-1 soluble vascular cell adhesion molecule
- the gene variability in exon 2 (Pro54Ala) of the intestinal fatty acid binding protein (FABP2) is decreased insulin sensitivity and increased occurrence of type 2 diabetes mellitus.
- Variability in the promoter of FABP2 is associated with decreased HDL levels and coupled with the Pro54Ala polymorphism results in increased postprandial triglycerides.
- the oral metabolic tolerance test was standardized as follows:
- vitamin A intervention resulted in changes in fasting and postprandial metabolism. These changes are dependent on the promoter variability.
- Fig. 1 shows the fasting triglycerin level before and after intervention as a function of the FABP2 promoter.
- Fig. 2 and 3 show the postprandial insulin level ( ⁇ U / ml) before intervention with retinol (- • -) and after intervention (-o-).
- Variant A Variant B
- Figs. 4 and 5 show the postprandial insulin level ( ⁇ U / ml); AUC; p ⁇ 0.05) and the postprandial insulin x glucose level ( ⁇ U / ml * mg / dl; AUC; p ⁇ 0.05), depending on the promoter variant.
- Figs. 6 and 7 show the postprandial free fatty acids (FFA). Hourly course (5) (mmol / ml) and AUC (6); p ⁇ 0.05; before intervention (- • -; ⁇ ) and after intervention with vitamin A (-o-; ⁇ ) independently of the FABP2 promoter variant. Even with genvisionn independent evaluation insulin levels and sensitivity and free fatty acid levels are reduced by vitamin A.
- the measurements show a reduction in free fatty acid as well as a direct decrease in insulin resistance.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE112006001247T DE112006001247A5 (en) | 2005-03-17 | 2006-03-16 | Retinol for lowering risk factors of atherosclerosis and / or increasing insulin sensitivity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005012831.9 | 2005-03-17 | ||
DE102005012831A DE102005012831A1 (en) | 2005-03-17 | 2005-03-17 | Preparation of a medicament for lowering the risk factor of atherosclerosis and / or increasing insulin sensitivity |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006097090A1 true WO2006097090A1 (en) | 2006-09-21 |
Family
ID=36463389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2006/000474 WO2006097090A1 (en) | 2005-03-17 | 2006-03-16 | Retinol for reducing risk factors of arteriosclerosis and/or increasing insulin sensitivity |
Country Status (2)
Country | Link |
---|---|
DE (2) | DE102005012831A1 (en) |
WO (1) | WO2006097090A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489611A (en) * | 1995-02-10 | 1996-02-06 | Warner-Lambert Company | Method for lowering plasma levels of lipoprotein (a) |
WO1996019215A1 (en) * | 1994-12-22 | 1996-06-27 | Henkel Corporation | Compositions of tocopherol and beta-carotene |
-
2005
- 2005-03-17 DE DE102005012831A patent/DE102005012831A1/en not_active Withdrawn
-
2006
- 2006-03-16 DE DE112006001247T patent/DE112006001247A5/en not_active Withdrawn
- 2006-03-16 WO PCT/DE2006/000474 patent/WO2006097090A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996019215A1 (en) * | 1994-12-22 | 1996-06-27 | Henkel Corporation | Compositions of tocopherol and beta-carotene |
US5489611A (en) * | 1995-02-10 | 1996-02-06 | Warner-Lambert Company | Method for lowering plasma levels of lipoprotein (a) |
Non-Patent Citations (7)
Title |
---|
BRATTSAND R: "Actions of vitamins A and E and some nicotinic acid derivatives on plasma lipids and on lipid infiltration of aorta in cholesterol-fed rabbits", ATHEROSCLEROSIS, AMSTERDAM, NL, vol. 22, no. 1, July 1975 (1975-07-01), pages 47 - 61, XP002119576, ISSN: 0021-9150 * |
FACCHINI FRANCESCO ET AL: "Relation between dietary vitamin intake and resistance to insulin-mediated glucose disposal in healthy volunteers", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 63, no. 6, 1996, pages 946 - 949, XP002383682, ISSN: 0002-9165 * |
HELWIG U ET AL: "Influence of retinol supplementation on triglyceride and insulin metabolism in persons with different FABP2 promoter genotypes", DIABETOLOGIA, vol. 48, no. Suppl. 1, 2005, & 41ST ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-DIAB ETES; ATHENS, GREECE; SEPTEMBER 10 -15, 2005, pages A273, XP009067317, ISSN: 0012-186X * |
LEVY Y ET AL: "DIETARY SUPPLEMENTATION OF A NATURAL ISOMER MIXTURE OF BETA-CAROTENE INHIBITS OXIDATION OF LDL DERIVED FROM PATIENTS WITH DIABETES MELLITUS", ANNALS OF NUTRITION AND METABOLISM, KARGER, CH, vol. 44, no. 2, March 2000 (2000-03-01), pages 54 - 60, XP009042880, ISSN: 0373-0101 * |
MEYERS DAVID G ET AL: "The Antioxidant Vitamins: Impact on Atherosclerosis", PHARMACOTHERAPY, vol. 13, no. 6, 1993, pages 574 - 582, XP009067350, ISSN: 0277-0008 * |
MURPHY NUALA ET AL: "Dietary antioxidants decrease serum soluble adhesion molecule (sVCAM-1, sICAM-1) but not chemokine (JE/MCP-1, KC) concentrations, and reduce atherosclerosis in C57BL but not apoE*3 Leiden mice fed an atherogenic diet.", DISEASE MARKERS. 2005, vol. 21, no. 4, 2005, pages 181 - 190, XP009067320, ISSN: 0278-0240 * |
SONG YOUNG-DUK ET AL: "Decreased plasma antioxidants, cryptoxanthin, beta-carotene, and retinol levels by hyperinsulinemia may be one of the factors promoting atherosclerosis in NIDDM patients", DIABETES, vol. 50, no. Supplement 2, June 2001 (2001-06-01), & 61ST SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION; PHILADELPHIA, PENNSYLVANIA, USA; JUNE 22-26, 2001, pages A463, XP009067318, ISSN: 0012-1797 * |
Also Published As
Publication number | Publication date |
---|---|
DE112006001247A5 (en) | 2008-02-14 |
DE102005012831A1 (en) | 2006-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tsai et al. | Effects of soy polysaccharide on postprandial plasma glucose, insulin, glucagon, pancreatic polypeptide, somatostatin, and triglyceride in obese diabetic patients | |
Escriva et al. | In vivo insulin-dependent glucose uptake of specific tissues is decreased during aging of mature Wistar rats | |
Kim et al. | Effect of dietary Platycodon grandiflorum on the improvement of insulin resistance in obese Zucker rats | |
WO1993021912A1 (en) | Use of an emulsion containing omega-3 fatty acids to produce a medicament to be parenterally administered for treating inflammatory diseases | |
Ince et al. | Breast milk β‐glucuronidase and prolonged jaundice in the neonate | |
WO2006097090A1 (en) | Retinol for reducing risk factors of arteriosclerosis and/or increasing insulin sensitivity | |
EP1242825B1 (en) | Extraction of lipoproteins from body fluids | |
DE2037942C2 (en) | Medicaments containing an "active" chondroitin sulfate as an active ingredient for preventing the occurrence of atherosclerotic lesions and for preventing the occurrence of heart attacks | |
DE102006036285A1 (en) | Whey permeate fractions and their use for the prevention and treatment of type 2 diabetes and metabolic syndrome | |
Tsukamoto et al. | Effects of a polyunsaturated fatty acid-rich diet on serum lipids in patients with chronic renal failure | |
Flatz | Serum-cholesterin, ABO-blutgruppen und haemoglobintyp | |
EP1687014B1 (en) | Use of additionally fermented distillers grains for preventing and/or treating increased blood sugar values | |
EP1667673B1 (en) | Alpha-linolenic acid-containing vegetable oils used against diabetes | |
Saada et al. | Effect of the Ramadan fasting on the variations of certain anthropometric and biochemical parameters in type 2 diabetic patients treated with medications mixture (biguanides and sulfamides) | |
Jösch et al. | Urin-Arylamidase | |
EP1644086B2 (en) | Use of whey permeate for the treatment of metabolic syndrome | |
Farquharson et al. | Pigment metabolism and destruction of blood in Addison's (pernicious) anemia | |
DE60306877T2 (en) | The blood fluidity improving foods | |
EP0349987B1 (en) | Fructosamine calibrator | |
Chourasia et al. | Evaluation of preliminary phytochemical analysis of Operculina turpethum roots extract for diabetic wound healing activity in rat | |
Borrelli et al. | Lipid peroxidation and lung ultrastructural changes in an experimental model of leukocyte-mediated pulmonary injury | |
Nema Al-Aridhi et al. | Serum Levels of Novel Biochemical Marker (Irisin) in Relation to the Duration of Type 2 Diabetes & in Cases of Type 2 diabetes with Coronary Artery Disease in Iraqi Patients Aged (40-60 year). | |
Suhasini et al. | Influence of unrefined sorghum or maize on serum lipids | |
Hailer et al. | Apolipoproteine und Lipide im Serum von Schwerverletzten in Abhängigkeit von der Ernährung | |
DE202023102781U1 (en) | Composition of an antidiabetic with hydroalcoholic extract of Ipomoea nil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1120060012479 Country of ref document: DE |
|
REF | Corresponds to |
Ref document number: 112006001247 Country of ref document: DE Date of ref document: 20080214 Kind code of ref document: P |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS, EPO FORM 1205A DD 21.12.2007 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06722630 Country of ref document: EP Kind code of ref document: A1 |